中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(6): 1075-1082

Efficacy and safety of coblopasvir hydrochloride combined with sofosbuvir in treatment of patients with genotype 3 hepatitis C virus infection

DOI: 10.12449/JCH250612
  • 1.

    Yunnan Provincial Clinical Medical Center for Infectious Diseases，The Third People’s Hospital of Kunming，Kunming 650041，China

  • 2.

    School of Public Health，Dali University，Dali，Yunnan 671000，China

Research funding:

Research Special Fund of You’an Vocational Alliance (LM202014)

More Information
  • Corresponding author: LIU Li， liuli197210@163.com （ORCID： 0000-0001-7712-4931）
  • Received Date: 2024-10-08
  • Accepted Date: 2024-10-30
  • Published Date: 2025-06-25
    Abstract
  •   Objective  To investigate the efficacy and safety of the direct-acting antiviral agents coblopasvir hydrochloride/sofosbuvir （CLP/SOF） regimen used alone or in combination with ribavirin （RBV） in the treatment of patients with genotype 3 hepatitis C virus （HCV） infection in terms of virologic response rate， liver function recovery， improvement in liver stiffness measurement （LSM）， and adverse drug reactions， and to provide a reference for clinical medication.  Methods  A total of 98 patients with genotype 3 HCV infection who attended The Third People’s Hospital of Kunming from January 2022 to December 2023 were enrolled， and according to the treatment method， the patients were divided into CLP/SOF+RBV treatment group with 55 patients and CLP/SOF treatment group with 43 patients. The patients were observed in terms of rapid virologic response at week 4 （RVR4）， sustained virologic response （SVR）， previous treatment experience， underlying diseases， laboratory and imaging indicators， and adverse reactions during treatment. The course of treatment was 12 weeks， and the patients were followed up for 12 weeks after drug withdrawal. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the Friedman test was used for comparison within each group at different time points， and the Bonferroni method was used for further comparison and correction of P value； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. The univariate and multivariate Logistic regression analyses were used to investigate the influencing factors for SVR12.  Results  Before treatment， there were significant differences between the CLP/SOF+RBV treatment group and the CLP/SOF treatment group in terms of LSM， total bilirubin （TBil）， gamma-glutamyl transpeptidase （GGT）， HCV genotype， and the presence or absence of liver cirrhosis and compensation （all P<0.05）. The 98 patients with genotype 3 HCV infection had an RVR4 rate of 81.6% and an SVR12 rate of 93.9%. The patients with genotype 3a HCV infection had an RVR4 rate of 84.44% and an SVR12 rate of 97.78%， while the patients with genotype 3b HCV infection had an RVR4 rate of 79.25% and an SVR12 rate of 90.57%. There were significant differences in RVR4 and SVR12 rates between the patients without hepatocellular carcinoma and those with hepatocellular carcinoma， there was a significant difference in RVR4 rate between the patients without HIV infection and those with HIV infection， and there was a significant difference in SVR12 rate between the previously untreated patients and the treatment-experienced patients （all P<0.05）. The univariate Logistic regression analysis showed that treatment history， hypertension， hepatocellular carcinoma， ascites， albumin （Alb）， and platelet count were influencing factors for SVR12 （all P<0.05）， and the multivariate Logistic regression analysis showed that hepatocellular carcinoma （odds ratio=0.034， 95% confidence interval： 0.002‍ ‍—‍‍ 0.666， P=0.026） was an independent influencing factor for SVR12. After treatment with CLP/SOF combined with RBV or CLP/SOF alone， the patients with genotype 3 HCV infection showed gradual reductions in the liver function parameters of TBil， GGT， and alanine aminotransferase （all P<0.05） and a gradual increase in the level of Alb （P<0.05）. As for renal function， there were no significant changes in blood urea nitrogen and creatinine after treatment （P>0.05）. For the patients with or without liver cirrhosis， there was a significant reduction in LSM from baseline after treatment for 12 weeks （P<0.05）. Among the 98 patients with genotype 3 HCV infection， 9 tested positive for HCV-RNA at 12 weeks after treatment， 2 showed no response during treatment， 4 showed virologic breakthrough， and 3 experienced recurrence. The overall incidence rate of adverse events during treatment was 17.35% for all patients.  Conclusion  CLP/SOF alone or in combination with RBV has a relatively high SVR rate in the treatment of genotype 3 HCV infection， with good tolerability and safety in patients during treatment， and therefore， it holds promise for clinical application.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.
    [2]
    HUSA P, SNOPKOVÁ S, HUSA ML P. Current hepatitis C therapy[J]. Cas Lek Cesk, 2022, 161( 2): 90- 93.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [4]
    BERNAL LA, SOTI V. Hepatitis C virus: Insights into its history, treatment, challenges, and future directions[J]. Cureus, 2023, 15( 8): e43924. DOI: 10.7759/cureus.43924.
    [5]
    YI CH, BAIR MJ, WANG JH, et al. Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection[J]. J Microbiol Immunol Infect, 2022, 55( 4): 643- 650. DOI: 10.1016/j.jmii.2022.04.011.
    [6]
    GAO YH, KONG F, LI GM, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial[J]. Liver Int, 2020, 40( 11): 2685- 2693. DOI: 10.1111/liv.14633.
    [7]
    ZHANG W, ZHAI S, DU H, et al. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C[J]. J Clin Hepatol, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.

    张伟, 翟嵩, 杜虹, 等. 12周索磷布韦联合可洛派韦治疗慢性丙型肝炎的效果和安全性分析[J]. 临床肝胆病杂志, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.
    [8]
    RAO HY, SONG GJ, LI GM, et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis[J]. J Viral Hepat, 2020, 27( 1): 45- 51. DOI: 10.1111/jvh.13208.
    [9]
    SHARAFI H, GHALAMKARI S, HASSANSHAHI A, et al. Pooled prevalence of NS5A resistance-associated substitutions in chronic HCV genotype 3 infection: A study based on deposited sequences in GenBank[J]. Microb Drug Resist, 2019, 25( 7): 1072- 1079. DOI: 10.1089/mdr.2018.0358.
    [10]
    ELSHEIKH MEA, MCCLURE CP, TARR AW, et al. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein(ARFP/core+1) in patients with chronic HCV genotype-3 infection[J]. J Gen Virol, 2022, 103( 3): 001727. DOI: 10.1099/jgv.0.001727.
    [11]
    ULLAH A, YU XJ, ODENTHAL M, et al. Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3[J]. PLoS One, 2022, 17( 5): e0268526. DOI: 10.1371/journal.pone.0268526.
    [12]
    LAPA D, DEL PORTO P, MINOSSE C, et al. Clinical relevance of torque teno virus(TTV) in HIV/HCV coinfected and HCV monoinfected patients treated with direct-acting antiviral therapy[J]. J Clin Med, 2021, 10( 10): 2092. DOI: 10.3390/jcm10102092.
    [13]
    AN J, PARK DA, KO MJ, et al. Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: A systematic review and meta-analysis[J]. J Pers Med, 2022, 12( 9): 1517. DOI: 10.3390/jpm12091517.
    [14]
    RIDRUEJO E, PIÑERO F, MENDIZABAL M, et al. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort[J]. J Med Virol, 2020, 92( 12): 3545- 3555. DOI: 10.1002/jmv.26383.
    [15]
    KUMADA T, TOYODA H, YASUDA S, et al. Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus[J]. Infect Dis Ther, 2021, 10( 2): 1001- 1013. DOI: 10.1007/s40121-021-00441-7.
    [16]
    YANG YQ, SHANG J, LU CZ, et al. Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C[J]. J Clin Hepatol, 2022, 38( 5): 1059- 1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016.

    杨宇晴, 尚佳, 卢诚震, 等. 直接抗病毒药物治疗丙型肝炎失败的影响因素分析[J]. 临床肝胆病杂志, 2022, 38( 5): 1059- 1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016.
    [17]
    FAROOQ HZ, JAMES M, ABBOTT J, et al. Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review[J]. World J Gastrointest Oncol, 2024, 16( 4): 1596- 1612. DOI: 10.4251/wjgo.v16.i4.1596.
    [18]
    KOZUKA R, TAMORI A, ENOMOTO M, et al. Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort[J]. J Viral Hepat, 2023, 30( 5): 374- 385. DOI: 10.1111/jvh.13795.
    [19]
    MOUSTAFA AH, PASHA HF, ABAS MA, et al. The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats[J]. Anat Cell Biol, 2023, 56( 1): 109- 121. DOI: 10.5115/acb.22.200.
    [20]
    ZENG H, LI L, HOU Z, et al. Direct-acting antiviral in the treatment of chronic hepatitis C: Bonuses and challenges[J]. Int J Med Sci, 2020, 17( 7): 892- 902. DOI: 10.7150/ijms.43079.
    [21]
    POLYAK SJ, CRISPE IN, BAUMERT TF. Liver abnormalities after elimination of HCV infection: Persistent epigenetic and immunological perturbations post-cure[J]. Pathogens, 2021, 10( 1): 44. DOI: 10.3390/pathogens10010044.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (693) PDF downloads(37) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return